Regeneron Pharmaceuticals Inc (REGN) Common Stock USD0.001

- Add to watchlist
- This stock can be held in a




Share news, reports & tips
-
Regeneron's monoclonal treatment for Covid-19 shows promise in early trial
30 September 2020 11:30
(Sharecast News) - Early trial results for Regeneron's monoclonal antibody cocktail showed that it helped to alleviate symptoms in patients in mild-to-moderate cases of Covid-19.
-
Sanofi to sell stake in Covid-19 treatment maker Regeneron
26 May 2020 11:59
(Sharecast News) - Sanofi will sell its stake in US-based maker of Covid-19 treatments Regeneron Pharmaceuticals.
-
Research into Covid-19 antibody therapy gaining ground - report
20 April 2020 14:10
(Sharecast News) - Antibody therapy for Covid-19 may be available by the autumn, according to a report on biotechnology firms carrying out research.
Company announcements Announcements
No company announcements about Regeneron Pharmaceuticals Inc Common Stock USD0.001 were found.
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.
© Digital Look Ltd 1998-2021. All rights reserved.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.